Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT07784959
Official study title

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

Study summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNXP900 and Lorlatinib

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · ALK

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 25, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Nuvectis Pharma, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Nuvectis Pharma, Inc.
Interventions being studied
Drug: NXP900; Drug: Lorlatinib
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Biomarkers
ALK→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • 18 years old or older
  • Unresectable, metastatic or locally advanced ALK-positive NSCLC.
  • Must have received lorlatinib as first or second line TKI
  • One prior line of systemic chemotherapy is permitted
  • Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose
Reasons someone may not be able to joinExclusion criteria
  • Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
  • Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • NEXT VirginiaFairfax, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 25, 2026. Always confirm current availability with the study team.

View original record ↗